{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:30:43Z","timestamp":1793395843195,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.actbio.2026.10.029","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:03:07Z","timestamp":1792162987000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polymeric nanoparticle gene delivery to reprogram the tumor immune microenvironment in ovarian cancer for an anti-tumor response"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-0635","authenticated-orcid":false,"given":"Joanna","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeongseo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Schmitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-7124","authenticated-orcid":false,"given":"Amanda I.","family":"Rakoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2108-6354","authenticated-orcid":false,"given":"Zoe","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5798-7987","authenticated-orcid":false,"given":"Ethan","family":"Idnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1896-7336","authenticated-orcid":false,"given":"Ethan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-3264","authenticated-orcid":false,"given":"Joshua C.","family":"Doloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-482X","authenticated-orcid":false,"given":"Stephany Y.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2026.10.029_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in Ovarian Cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"11","key":"10.1016\/j.actbio.2026.10.029_bib0002","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2026.10.029_bib0003","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.actbio.2026.10.029_bib0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canep.2017.12.003","article-title":"Epithelial ovarian cancer mortality among Hispanic women: sub-ethnic disparities and survival trend across time: an analysis of SEER 1992-2013","volume":"52","author":"Chen","year":"2018","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3802\/jgo.2013.24.1.83","article-title":"Advanced ovarian cancer: what should be the standard of care?","volume":"24","author":"Goff","year":"2013","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102074","article-title":"Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study","volume":"76","author":"Gaitskell","year":"2022","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.actbio.2026.10.029_bib0007","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.actbio.2026.10.029_bib0008","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/diagnostics15040406","article-title":"Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions","volume":"15","author":"Hong","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.actbio.2026.10.029_bib0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/21691401.2013.853179","article-title":"The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer","volume":"43","author":"Gidwani","year":"2015","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41419-023-05859-0","article-title":"Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.actbio.2026.10.029_bib0011","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2026.10.029_bib0013","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0014","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0015","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3906\/sag-2005-327","article-title":"Immune gene therapy of cancer","volume":"50","author":"Akbulut","year":"2020","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.actbio.2026.10.029_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102115","article-title":"Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies","volume":"23","author":"Choi","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.actbio.2026.10.029_bib0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2017.03.384","article-title":"Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma","volume":"263","author":"Zamboni","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.10.029_bib0018","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1073\/pnas.1916039117","article-title":"In situ genetic engineering of tumors for long-lasting and systemic immunotherapy","volume":"117","author":"Tzeng","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.actbio.2026.10.029_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122185","article-title":"Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors","volume":"300","author":"Neshat","year":"2023","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.actbio.2026.10.029_bib0020","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1021\/acsbiomaterials.3c00885","article-title":"Biomaterial-mediated genetic reprogramming of merkel cell carcinoma and melanoma leads to targeted cancer cell killing in vitro and in vivo","volume":"9","author":"Luly","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.actbio.2026.10.029_bib0021","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)64505-1","article-title":"Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma","volume":"161","author":"Zhang","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0022","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.gt.3302974","article-title":"Control of human mesothelin-expressing tumors by DNA vaccines","volume":"14","author":"Chang","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.actbio.2026.10.029_bib0023","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-5876-6-2","article-title":"Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer","volume":"6","author":"Holtz","year":"2008","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.actbio.2026.10.029_bib0024","first-page":"2785","article-title":"Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer","volume":"26","author":"Jan\u00e1t-Amsbury","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.actbio.2026.10.029_bib0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.actbio.2026.10.029_bib0026","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12958-023-01125-2","article-title":"Liposomal delivery of gene therapy for ovarian cancer: a systematic review","volume":"21","author":"Son","year":"2023","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0028","first-page":"191","article-title":"Manganese and IL-12 treatment alters the ovarian tumor microenvironment","volume":"16","author":"Xu","year":"2024","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.actbio.2026.10.029_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2198185","article-title":"Immunotherapy with IL12 and PD1\/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression","volume":"12","author":"Pavicic","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.actbio.2026.10.029_bib0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2017.05.005","article-title":"Surface engineering for lymphocyte programming","volume":"114","author":"Ben-Akiva","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.10.029_bib0031","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","article-title":"Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells","volume":"162","author":"Curtsinger","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012856","article-title":"Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2\/3 gene delivery","volume":"14","author":"Luly","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.actbio.2026.10.029_bib0034","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/2326-6066.CIR-19-0258","article-title":"Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced stage ovarian cancer","volume":"7","author":"Anderson","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.actbio.2026.10.029_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.07.002","article-title":"Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer","volume":"461","author":"Parayath","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2026.10.029_bib0036","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0037","series-title":"Holland-Frei Cancer Medicine","article-title":"Epithelial ovarian cancer","author":"Berek","year":"2003"},{"issue":"1","key":"10.1016\/j.actbio.2026.10.029_bib0038","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2520266","article-title":"The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis","volume":"14","author":"Gomar","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.actbio.2026.10.029_bib0039","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0654-5","article-title":"Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer","volume":"7","author":"Hartl","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.actbio.2026.10.029_bib0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2026.10.029_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103757","article-title":"CD4+CD8+ double-positive T cells in immune disorders and cancer: prospects and hurdles in immunotherapy","volume":"24","author":"Alam","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.actbio.2026.10.029_bib0042","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ijc.24366","article-title":"Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions","volume":"125","author":"Desfran\u00e7ois","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.actbio.2026.10.029_bib0043","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212169","article-title":"Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions","volume":"219","author":"Schad","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2026.10.029_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008437","article-title":"Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas","volume":"5","author":"Desfran\u00e7ois","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.actbio.2026.10.029_bib0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","article-title":"Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.10.029_bib0046","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","article-title":"Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer","volume":"15","author":"Kasikova","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2026.10.029_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1473969","article-title":"Tertiary lymphoid structures: exploring opportunities to improve immunotherapy in ovarian cancer","volume":"16","author":"Varghese","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2026.10.029_bib0048","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.ccell.2024.09.007","article-title":"The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions","volume":"42","author":"MacFawn","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.actbio.2026.10.029_bib0049","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/rr41","article-title":"Th2 cytokines and asthma\u2013The role of interleukin-5 in allergic eosinophilic disease","volume":"2","author":"Greenfeder","year":"2001","journal-title":"Respir. Res."},{"key":"10.1016\/j.actbio.2026.10.029_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115976","article-title":"Polysaccharides regulate Th1\/Th2 balance: a new strategy for tumor immunotherapy","volume":"170","author":"Shang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.actbio.2026.10.029_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.actbio.2026.10.029_bib0052","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1075113","article-title":"Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination","volume":"5","author":"Llopiz","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.actbio.2026.10.029_bib0053","doi-asserted-by":"crossref","first-page":"27158","DOI":"10.1074\/jbc.M115.682708","article-title":"Interleukin 10 (IL-10)-mediated Immunosuppression","volume":"290","author":"Mittal","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.actbio.2026.10.029_bib0054","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mi.2016.47","article-title":"CD4+ Th2 cells are directly regulated by IL-10 during allergic airway inflammation","volume":"10","author":"Coomes","year":"2017","journal-title":"Mucosal Immunol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126007075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126007075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:41:14Z","timestamp":1793392874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706126007075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"alternative-id":["S1742706126007075"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2026.10.029","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymeric nanoparticle gene delivery to reprogram the tumor immune microenvironment in ovarian cancer for an anti-tumor response","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2026.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}